https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html Drugnews｜藥時事 zh-tw 2026-10-11T07:19:01.000Z 兒少肥胖用藥：Novo 的先發優勢，為何還要靠 Wegovy 接棒？ https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll-en.html Drugnews｜藥時事 en 2026-10-11T00:00:00.000Z Lilly’s blood-cancer drug moves earlier. Which contest has it won? https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll.html Drugnews｜藥時事 zh-tw 2026-10-11T00:00:00.000Z 禮來血癌藥提前上場，贏的是哪場仗？ https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay-en.html Drugnews｜藥時事 en 2026-10-10T00:00:00.000Z Fewer bleeds. Why is Novo’s new drug still waiting outside the US? https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html Drugnews｜藥時事 zh-tw 2026-10-10T00:00:00.000Z 出血少了，新藥為何還進不了美國？